Ticker Details
Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its products portfolio includes Glybera, TV-45070.
IPO Date:	November 5, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$5.24B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.47 | 2.45%
Avg Daily Range (30 D):	$0.72 | 1.27%
Avg Daily Range (90 D):	$0.83 | 1.64%

Institutional Daily Volume
Avg Daily Volume:	.31M
Avg Daily Volume (30 D):	.74M
Avg Daily Volume (90 D):	1.04M

Trade Size
Avg Trade Size (Sh.):	80
Avg Trade Size (Sh.) (30 D):	54
Avg Trade Size (Sh.) (90 D):	62

Institutional Trades
Total Institutional Trades:	3,010
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$2.95M
Avg Institutional Trade (90 D):	$2.78M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.37M
Avg Closing Trade (30 D):	$6.64M
Avg Closing Trade (90 D):	$6.79M
Avg Closing Volume:	61.28K

News

Apr 19, 2026 @ 10:00 PM Xenon Presents Azetukalner Phase 3 X-TOLE2 Study R... Source: Xenon Pharmaceuticals Inc.

Mar 27, 2026 @ 11:03 PM Xenon Pharma Stock Up 55% as Insider Sells $78K in... Source: Jonathan Ponciano

Mar 11, 2026 @ 2:39 AM Xenon Pharmaceuticals Announces Pricing of Upsized... Source: Na

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Dec 4, 2025 @ 10:20 PM Xenon Pharmaceuticals Reports Inducement Grants Un... Source: Xenon Pharmaceuticals Inc.

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-4.7	$-1.17	$-1.31
Diluted EPS	$-4.7	$-1.17	$-1.31
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-383.17M	$-102.3M	$-105.26M
Operating Income / Loss	$-412.66M	$-112.33M	$-109.77M
Cost of Revenue
Net Cash Flow	$429.21M	$346.7M	$94.65M
PE Ratio